BTG PLC AGM Statement (9169K)
July 13 2017 - 1:00AM
UK Regulatory
TIDMBTG
RNS Number : 9169K
BTG PLC
13 July 2017
BTG plc: Annual General Meeting
London, UK, 13 July 2017: BTG plc (LSE: BTG), the global
specialist healthcare company, provides the following update ahead
of its Annual General Meeting, which is being held today at 10.30am
at the offices of Stephenson Harwood LLP, 1 Finsbury Circus,
London, EC2M 7SH.
At the meeting, the Board will comment on the performance of the
Group in the year ended 31 March 2017, as detailed in the results
announcement on 16 May 2017, and describe progress made in the
current financial year to date.
Louise Makin, Chief Executive Officer, commented: "Our strong
performance in 2016/17 has continued into the new financial year.
We are on track to achieve double-digit product sales growth over
the full financial year, driven by growth in our Interventional
Medicine business. We reported positive outcomes from two EKOS
clinical studies in the first quarter and we anticipate further
progress across the portfolio over the full year, including
reaching important milestones for Varithena(R) and the PneumRx(R)
Coils. We will continue to implement our growth strategy, to
deliver double-digit annual product sales growth and margin
expansion over time whilst investing selectively in innovation and
development, commercial and geographic expansion and acquisitions
to ensure sustainable long-term value creation."
Trading since 1 April 2017 has been in line with the Board's
expectations and guidance for the full year is unchanged. There
were strong performances from TheraSphere(R) , the liver cancer
treatment, and EKOS(R) , the blood clot treatment device. Varithena
continues to make progress ahead of the publication of new
reimbursement codes expected towards the end of the year. The
antivenin CroFab(R) made a good start to the new snakebite season
and there was a good performance from Voraxaze(R) , used to treat
methotrexate toxicity in patients with impaired renal function.
There was also good operating progress. Positive data were
reported from two clinical studies using EKOS(R) . The OPTALYSE
study demonstrated the safety and efficacy of shorter, lower-dose
EKOS(R) therapy for pulmonary embolism, and the ACCESS PTS study
demonstrated the safety and efficacy of an EKOS(R) therapy
treatment regimen for post-thrombotic syndrome.
A pilot study showed sustained quality of life at regular
intervals throughout three months in patients treated with
TheraSphere(R) using IO Loop(TM), a novel data collection tool that
helps patients better engage in their own healthcare and measures
quality of life and satisfaction rates across the course of their
treatment.
In June 2017, the Society of Interventional Oncology and BTG
announced their 2017 interventional oncology/immuno-oncology grant
recipients. This research grant programme funds initiatives that
evaluate how interventional oncology therapies stimulate the immune
system and how they might combine with immunotherapy approaches to
improve clinical outcomes.
Work continues to progress the Premarket Approval application in
the US for the PneumRx(R) Coils, and in Europe
coverage/reimbursement determinations continue in Germany and
France.
For further information contact:
BTG FTI Consulting
Andy Burrows, VP Corporate Ben Atwell/Simon Conway
& Investor Relations +44 (0)20 3727 1000
+44 (0)20 7575 1741; Mobile:
+44 (0)7990 530 605
Stuart Hunt, Investor Relations
Manager
+44 (0)20 7575 1582; Mobile:
+44 (0)7815 778 536
Chris Sampson, Corporate
Communications Director
+44 (0)20 7575 1595; Mobile:
+44 (0)7773 251 178
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMRTMFTMBJBBRR
(END) Dow Jones Newswires
July 13, 2017 02:00 ET (06:00 GMT)
Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024
Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024